Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia

BASEL, Switzerland, Nov. 18, 2024 /PRNewswire/ — Vaderis Therapeutics AG (Vaderis), a clinical stage biotechnology company focusing on treatments for rare diseases associated with vascular malformations, today announces that the US Food and Drug Administration (FDA) has designated the allosteric AKT-inhibitor VAD044 a Fast Track product for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT). Fast […] L'articolo Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia proviene da La Ragione.

CONTINUA A LEGGERE